Climb Bio (CLYM) Competitors $1.95 0.00 (0.00%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsInsider TradesSEC FilingsTrends CLYM vs. ORIC, ATXS, ANNX, SVRA, MREO, PRTC, ABVX, CRMD, TERN, and XERSShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include ORIC Pharmaceuticals (ORIC), Astria Therapeutics (ATXS), Annexon (ANNX), Savara (SVRA), Mereo BioPharma Group (MREO), PureTech Health (PRTC), ABIVAX Société Anonyme (ABVX), CorMedix (CRMD), Terns Pharmaceuticals (TERN), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical preparations" industry. Climb Bio vs. ORIC Pharmaceuticals Astria Therapeutics Annexon Savara Mereo BioPharma Group PureTech Health ABIVAX Société Anonyme CorMedix Terns Pharmaceuticals Xeris Biopharma ORIC Pharmaceuticals (NASDAQ:ORIC) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment. Do insiders and institutionals hold more shares of ORIC or CLYM? 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 3.2% of Climb Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is ORIC or CLYM more profitable? Climb Bio's return on equity of -42.21% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -42.47% -38.86% Climb Bio N/A -42.21%-41.39% Does the MarketBeat Community prefer ORIC or CLYM? ORIC Pharmaceuticals received 60 more outperform votes than Climb Bio when rated by MarketBeat users. However, 100.00% of users gave Climb Bio an outperform vote while only 72.09% of users gave ORIC Pharmaceuticals an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% Climb BioOutperform Votes2100.00% Underperform VotesNo Votes Which has better earnings & valuation, ORIC or CLYM? ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-4.56Climb BioN/AN/A-$35.12M-$2.13-0.92 Does the media refer more to ORIC or CLYM? In the previous week, ORIC Pharmaceuticals had 6 more articles in the media than Climb Bio. MarketBeat recorded 9 mentions for ORIC Pharmaceuticals and 3 mentions for Climb Bio. ORIC Pharmaceuticals' average media sentiment score of 0.53 beat Climb Bio's score of 0.25 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ORIC or CLYM? ORIC Pharmaceuticals currently has a consensus target price of $18.29, suggesting a potential upside of 122.72%. Climb Bio has a consensus target price of $10.00, suggesting a potential upside of 412.82%. Given Climb Bio's stronger consensus rating and higher possible upside, analysts clearly believe Climb Bio is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Climb Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has more risk & volatility, ORIC or CLYM? ORIC Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500. Comparatively, Climb Bio has a beta of -0.4, meaning that its stock price is 140% less volatile than the S&P 500. SummaryORIC Pharmaceuticals beats Climb Bio on 9 of the 16 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.09M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.9210.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book0.505.094.784.78Net Income-$35.12M$151.83M$120.31M$225.60M7 Day Performance-25.00%-2.14%-1.92%-1.23%1 Month PerformanceN/A-4.56%13.65%0.46%1 Year PerformanceN/A8.87%28.34%15.24% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio3.3205 of 5 stars$1.95flat$10.00+412.8%N/A$131.09MN/A-0.92N/ANews CoverageHigh Trading VolumeORICORIC Pharmaceuticals3.6882 of 5 stars$7.68-6.9%$18.29+138.1%-7.4%$541.96MN/A-4.2780Insider TradeATXSAstria Therapeutics2.0732 of 5 stars$9.36-2.0%$25.60+173.5%+53.5%$528.22MN/A-4.4830News CoverageANNXAnnexon2.1121 of 5 stars$4.95+1.4%$15.80+219.2%+40.2%$527.64MN/A-4.7160Analyst ForecastNews CoverageGap DownSVRASavara3.0636 of 5 stars$3.02-6.2%$10.17+236.6%-31.1%$518.29MN/A-7.02N/AAnalyst ForecastNews CoverageMREOMereo BioPharma Group2.0938 of 5 stars$3.31-2.6%$7.40+123.6%+63.4%$513.53M$1M0.0040PRTCPureTech Health1.9892 of 5 stars$21.05-3.4%$45.00+113.8%+8.9%$503.98M$3.33M0.00100Gap DownABVXABIVAX Société Anonyme2.2073 of 5 stars$7.80-1.8%$38.67+395.7%-29.2%$494.11MN/A0.0061Positive NewsGap UpCRMDCorMedix1.8423 of 5 stars$8.12-4.9%$15.20+87.2%+137.4%$492.70M$12.26M-10.0230Analyst ForecastNews CoveragePositive NewsTERNTerns Pharmaceuticals4.2467 of 5 stars$5.76-15.3%$18.30+217.7%-7.6%$489.25M$1M-4.8840Positive NewsGap DownHigh Trading VolumeXERSXeris Biopharma3.6008 of 5 stars$3.25-4.7%$4.87+49.7%+66.2%$484.51M$187.36M-7.22290News CoveragePositive News Related Companies and Tools Related Companies ORIC Pharmaceuticals Competitors Astria Therapeutics Competitors Annexon Competitors Savara Competitors Mereo BioPharma Group Competitors PureTech Health Competitors ABIVAX Société Anonyme Competitors CorMedix Competitors Terns Pharmaceuticals Competitors Xeris Biopharma Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CLYM) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
